These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 12625847)

  • 1. Cardiovascular safety of PDE5 inhibitors.
    Herschorn S
    Can J Urol; 2003 Feb; 10 Suppl 1():23-8. PubMed ID: 12625847
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Sildenafil citrate for erectile dysfunction in men with diabetes and cardiovascular risk factors: a retrospective analysis of pooled data from placebo-controlled trials.
    Blonde L
    Curr Med Res Opin; 2006 Nov; 22(11):2111-20. PubMed ID: 17076971
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sexual dysfunction and cardiac risk (the Second Princeton Consensus Conference).
    Kostis JB; Jackson G; Rosen R; Barrett-Connor E; Billups K; Burnett AL; Carson C; Cheitlin M; Debusk R; Fonseca V; Ganz P; Goldstein I; Guay A; Hatzichristou D; Hollander JE; Hutter A; Katz S; Kloner RA; Mittleman M; Montorsi F; Montorsi P; Nehra A; Sadovsky R; Shabsigh R
    Am J Cardiol; 2005 Jul; 96(2):313-21. PubMed ID: 16018863
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Sex, erectile dysfunction, and the heart: a growing problem].
    Görge G; Flüchter S; Kirstein M; Kunz T
    Herz; 2003 Jun; 28(4):284-90. PubMed ID: 12825143
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erectile dysfunction in patients with coronary artery disease.
    Kloner R; Padma-Nathan H
    Int J Impot Res; 2005; 17(3):209-15. PubMed ID: 15729374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cardiovascular safety of sildenafil citrate (Viagra): an updated perspective.
    Jackson G; Montorsi P; Cheitlin MD
    Urology; 2006 Sep; 68(3 Suppl):47-60. PubMed ID: 17011375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacotherapy of erectile dysfunction: focus on cardiovascular safety.
    Reffelmann T; Kloner RA
    Expert Opin Drug Saf; 2005 May; 4(3):531-40. PubMed ID: 15934858
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Update of PDE5 inhibitors as treatment of ED].
    Lu YN; Chen B
    Zhonghua Nan Ke Xue; 2005 Jul; 11(7):552-5. PubMed ID: 16078679
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Erectile dysfunction, sildenafil and cardiovascular risk.
    Chew KK; Stuckey BG; Thompson PL
    Med J Aust; 2000 Mar; 172(6):279-83. PubMed ID: 10860094
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cardiovascular risk factors determine erectile and arterial function response to sildenafil.
    Solomon H; Wierzbicki AS; Lumb PJ; Lambert-Hammill M; Jackson G
    Am J Hypertens; 2006 Sep; 19(9):915-9. PubMed ID: 16942933
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Update on oral treatments for male erectile dysfunction.
    Kalsi JS; Kell PD
    J Eur Acad Dermatol Venereol; 2004 May; 18(3):267-74. PubMed ID: 15096134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Efficacy and safety of phosphodiesterase 5 inhibitors in the treatment of erectile dysfunction].
    Shen ZJ; Yu YL
    Zhonghua Nan Ke Xue; 2005 Aug; 11(8):631-4. PubMed ID: 16138588
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Emerging oral drugs for erectile dysfunction.
    Briganti A; Salonia A; Gallina A; Suardi N; Rigatti P; Montorsi F
    Expert Opin Emerg Drugs; 2004 May; 9(1):179-89. PubMed ID: 15155143
    [TBL] [Abstract][Full Text] [Related]  

  • 14. [The safety of 5-phosphodiesterase inhibitors in the treatment of erectile dysfunction in patients with cardiovascular disease].
    Bryniarski L; Rzepecki M; Klocek M; Wyczołkowski M
    Przegl Lek; 2009; 66(4):192-7. PubMed ID: 19708509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Erectile dysfunction: evaluation and new treatment options.
    Carson CC
    Psychosom Med; 2004; 66(5):664-71. PubMed ID: 15385689
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Sildenafil citrate for erectile dysfunction in men receiving multiple antihypertensive agents: a randomized controlled trial.
    Pickering TG; Shepherd AM; Puddey I; Glasser DB; Orazem J; Sherman N; Mancia G
    Am J Hypertens; 2004 Dec; 17(12 Pt 1):1135-42. PubMed ID: 15607620
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factors associated with preference for sildenafil citrate and tadalafil for treating erectile dysfunction in men naïve to phosphodiesterase 5 inhibitor therapy: post hoc analysis of data from a multicentre, randomized, open-label, crossover study.
    Eardley I; Montorsi F; Jackson G; Mirone V; Chan ML; Loughney K; Vail GM; Beardsworth A
    BJU Int; 2007 Jul; 100(1):122-9. PubMed ID: 17552960
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Safety and efficacy of sildenafil citrate in treating erectile dysfunction in patients with combat-related post-traumatic stress disorder: a double-blind, randomized and placebo-controlled study.
    Safarinejad MR; Kolahi AA; Ghaedi G
    BJU Int; 2009 Aug; 104(3):376-83. PubMed ID: 19389004
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Managing sexual dysfunction. Using sildenafil for patients with cardiovascular disease. Heart and Stroke Foundation of Canada. Canadian Cardiovascular Society.
    Can Fam Physician; 2000 Feb; 46():393, 398. PubMed ID: 10690496
    [No Abstract]   [Full Text] [Related]  

  • 20. Phosphodiesterase 5 inhibitors for erectile dysfunction.
    Setter SM; Iltz JL; Fincham JE; Campbell RK; Baker DE
    Ann Pharmacother; 2005; 39(7-8):1286-95. PubMed ID: 15941818
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.